Key Segments:
By Drug Class
-
Disease-Modifying Therapies
-
Neuroprotective Drugs
-
Gene & RNA Therapies
-
Symptomatic Therapies
-
Others
By Disease Type
-
Sporadic ALS
-
Familial ALS
By Route of Administration
-
Oral
-
Intravenous Infusion
-
Intrathecal Administration
-
Subcutaneous Injection
-
Others
By End User
-
Hospitals
-
Neurology Specialty Clinics
-
Retail & Specialty Pharmacies
-
Academic & Research Institutes
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market was valued at USD 1.08 Billion in 2025.
The market is projected to reach USD 1.85 Billion by 2035.
The market is expected to expand at a CAGR of 7.97% during 2026–2035.
Disease-Modifying Therapies accounted for the largest revenue share with 34.00% in 2025.